Boxer Capital’s Cartesian Therapeutics RNAC Stock Holding History

Boxer Capital’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-109,469	Closed	-$3.68M	–	79
2023 Q2	$3.68M	Hold	109,469	–	–	0.17%	58
2023 Q1	$4.57M	Hold	109,469	–	–	0.22%	53
2022 Q4	$3.71M	Hold	109,469	–	–	0.2%	52
2022 Q3	$5.39M	Hold	109,469	–	–	0.3%	51
2022 Q2	$4.3M	Hold	109,469	–	–	0.27%	58
2022 Q1	$4.04M	Hold	109,469	–	–	0.21%	60
2021 Q4	$10.7M	Hold	109,469	–	–	0.42%	45
2021 Q3	$13.7M	Hold	109,469	–	–	0.48%	54
2021 Q2	$13.7M	Hold	109,469	–	–	0.48%	61
2021 Q1	$14.9M	Hold	109,469	–	–	0.5%	54
2020 Q4	$9.95M	Hold	109,469	–	–	0.32%	55
2020 Q3	$8.14M	Hold	109,469	–	–	0.28%	57
2020 Q2	$9.33M	Hold	109,469	–	–	0.41%	48
2020 Q1	$7.92M	Hold	109,469	–	–	0.54%	43
2019 Q4	$7.82M	Buy	+109,469	New	+$5.28M	0.44%	41

Other funds holding RNAC

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Boxer Capital's RNAC Position: Q3 2023 in Review

Boxer Capital sold out of Cartesian Therapeutics (RNAC) in Q3 2023, closing a stake of 109,469 shares — an estimated $3.68M sold.

Boxer Capital first reported a position in RNAC in Q4 2019 and held it in 15 quarters. The position peaked at $14.9M in Q1 2021. 87 funds tracked by Wall St. Rank hold RNAC as of Q3 2023.

Boxer Capital reported no remaining Cartesian Therapeutics position as of Q3 2023 after selling out during the quarter.
Boxer Capital sold 109,469 Cartesian Therapeutics shares in Q3 2023, an estimated $3.68M.
Boxer Capital first reported a position in Cartesian Therapeutics in Q4 2019 and held it in 15 quarters.
Boxer Capital's Cartesian Therapeutics position peaked at $14.9M in Q1 2021.
87 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2023.

Based on Boxer Capital's 13F filing for Q3 2023, filed 14 Nov 2023.